Chuling Zhuang
Overview
Explore the profile of Chuling Zhuang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
4
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yu Y, Arrigo A, Chandra A, Zhuang C, Najjar M, Khan M, et al.
bioRxiv
. 2025 Mar;
PMID: 40060625
Glioblastoma (GBM) remains the most aggressive primary brain tumor in adults, with no effective treatments. While cyclin-dependent kinase 4/6 inhibitors (CDK4/6is) show clinical promise in some cancers, they have not...
2.
Manore S, Zhuang C, Najjar M, Wong G, Bindal S, Watabe K, et al.
Cells
. 2025 Jan;
13(24).
PMID: 39768178
Breast cancer stem cells (CSCs) are resistant to most cancer therapeutics and contribute to tumor recurrence and metastasis. Two breast CSC-promoting transcription factors, truncated glioma-associated oncogene homolog 1 (tGLI1) and...
3.
Najjar M, Khan M, Zhuang C, Chandra A, Lo H
Cells
. 2024 Oct;
13(20.
PMID: 39451208
Interleukin-1 Receptor Associated Kinase 1 (IRAK1) is a serine/threonine kinase that plays a critical role as a signaling transducer of the activated Toll-like receptor (TLR)/Interleukin-1 receptor (IL-1R) signaling pathway in...
4.
Khan M, Wong G, Zhuang C, Najjar M, Lo H
Front Oncol
. 2024 Aug;
14:1436942.
PMID: 39175471
Breast cancer is the most frequent malignancy in women, constituting 15.2% of all new cancers diagnosed in the United States. Distant breast cancer metastasis accounts for the majority of breast...
5.
Regua A, Bindal S, Najjar M, Zhuang C, Khan M, Arrigo A, et al.
Cancer Lett
. 2024 Jun;
597:217023.
PMID: 38852701
HER2-positive and triple-negative breast cancers (TNBC) are difficult to treat and associated with poor prognosis. Despite showing initial response, HER2-positive breast cancers often acquire resistance to HER2-targeted therapies, and TNBC...
6.
Zhuang C, Yang S, Gonzalez C, Ainsworth R, Li S, Kobayashi M, et al.
J Biol Chem
. 2024 May;
300(6):107393.
PMID: 38777143
Protein tyrosine phosphatase nonreceptor type 22 (PTPN22) is encoded by a major autoimmunity gene and is a known inhibitor of T cell receptor (TCR) signaling and drug target for cancer...